South Korea · Delayed Price · Currency is KRW IntoCell Statistics
Total Valuation
IntoCell has a market cap or net worth of KRW 335.74 billion. The enterprise value is 318.54 billion.
| Market Cap | 335.74B |
| Enterprise Value | 318.54B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
IntoCell has 15.02 million shares outstanding. The number of shares has increased by 11.53% in one year.
| Current Share Class | 15.02M |
| Shares Outstanding | 15.02M |
| Shares Change (YoY) | +11.53% |
| Shares Change (QoQ) | +0.76% |
| Owned by Insiders (%) | 21.89% |
| Owned by Institutions (%) | 9.45% |
| Float | 11.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 135.87 |
| PB Ratio | 15.78 |
| P/TBV Ratio | 20.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 128.90 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.92, with a Debt / Equity ratio of 0.48.
| Current Ratio | 6.92 |
| Quick Ratio | 6.80 |
| Debt / Equity | 0.48 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.02 |
| Interest Coverage | -38.06 |
Financial Efficiency
Return on equity (ROE) is -89.26% and return on invested capital (ROIC) is -28.62%.
| Return on Equity (ROE) | -89.26% |
| Return on Assets (ROA) | -21.30% |
| Return on Invested Capital (ROIC) | -28.62% |
| Return on Capital Employed (ROCE) | -30.16% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.57% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -36.57% |
| 50-Day Moving Average | 34,516.00 |
| 200-Day Moving Average | 45,018.25 |
| Relative Strength Index (RSI) | 26.13 |
| Average Volume (20 Days) | 79,509 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, IntoCell had revenue of KRW 2.47 billion and -11.24 billion in losses. Loss per share was -765.42.
| Revenue | 2.47B |
| Gross Profit | 2.47B |
| Operating Income | -10.42B |
| Pretax Income | -11.24B |
| Net Income | -11.24B |
| EBITDA | -9.64B |
| EBIT | -10.42B |
| Loss Per Share | -765.42 |
Balance Sheet
The company has 27.44 billion in cash and 10.24 billion in debt, with a net cash position of 17.20 billion or 1,145.18 per share.
| Cash & Cash Equivalents | 27.44B |
| Total Debt | 10.24B |
| Net Cash | 17.20B |
| Net Cash Per Share | 1,145.18 |
| Equity (Book Value) | 21.28B |
| Book Value Per Share | 1,417.19 |
| Working Capital | 24.15B |
Cash Flow
In the last 12 months, operating cash flow was -9.98 billion and capital expenditures -103.51 million, giving a free cash flow of -10.08 billion.
| Operating Cash Flow | -9.98B |
| Capital Expenditures | -103.51M |
| Depreciation & Amortization | 784.85M |
| Net Borrowing | -28.70M |
| Free Cash Flow | -10.08B |
| FCF Per Share | -671.25 |
Margins
| Gross Margin | 99.81% |
| Operating Margin | -421.76% |
| Pretax Margin | -454.99% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IntoCell does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.53% |
| Shareholder Yield | -11.53% |
| Earnings Yield | -3.35% |
| FCF Yield | -3.00% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
IntoCell has an Altman Z-Score of 19.37 and a Piotroski F-Score of 3.
| Altman Z-Score | 19.37 |
| Piotroski F-Score | 3 |